CAR-T TREATMENT
PROCESS
The complete arc from evaluation to follow-up โ 8 phases spanning 4-8 weeks. Each step has its own timeline, complications, and decision points.
analyticsAt a Glance
- check_circleStep 1: Leukapheresis โ T-cells collected from the patient's blood
- check_circleStep 2: Manufacturing โ cells are engineered with a CAR gene in a specialist facility (3โ5 weeks)
- check_circleStep 3: Conditioning chemotherapy is given before infusion to prepare the immune system
- check_circleStep 4: CAR-T infusion, followed by close monitoring for cytokine release and neurotoxicity
The Full Arc of CAR-T Treatment
From decision to infusion, most patients face 4-8 weeks. The timeline is built into the biology โ cells need to be collected, modified, expanded, and quality-tested. Understanding each phase helps patients prepare for a significant but structured commitment.
8 Phases of CAR-T Treatment
- 1
Pre-Treatment Evaluation & Consent
Disease confirmation, organ function, cardiac baseline, infectious screening, and substantive consent conversation.
- 2
Leukapheresis
T-cells collected via apheresis. Day procedure, 3-6 hours. Mild fatigue common.
- 3
Manufacturing
T-cells genetically modified with CAR construct and expanded. Patient at home or receiving bridging therapy.
- 4
Bridging Therapy
Treatment to keep disease stable during manufacturing. Not always needed; type depends on cancer and urgency.
- 5
Lymphodepletion Chemotherapy
Fludarabine + cyclophosphamide for 3 days. Creates immune space for CAR-T engraftment.
- 6
CAR-T Infusion
IV administration, less than an hour. The complexity is in the days that follow.
- 7
Post-Infusion Monitoring
Inpatient 7-14 days. CRS and ICANS monitoring with vital signs, neuro checks, cytokine levels.
- 8
Follow-Up & Response Assessment
Regular blood tests, imaging. Response evaluated at ~1 month, then at intervals.
Frequently Asked Questions
About the Process
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Planning Your CAR-T Treatment Journey?
Upload your reports and we will walk through the specific timeline and logistics for your case.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.